Real-World Outcomes of Second-Line Treatment in Sensitive Relapsed Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study
Fatih Gurler1, Aysegul Ilhan Gulesen1, Hakan Taban2, Funda Yilmaz1, Erdogan Seyran1, Esma Dursun3, Emrah Eraslan4, Zafer Arik2, Berna Oksuzoglu1, Ozan Yazici5, Nuriye Ozdemir5, Aytug Uner5, Nazan Gunel5, Ahmet Ozet51Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Türkiye, 2Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Türkiye, 3Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye, 4Department of Medical Oncology, Koru Hospital, Ankara, Türkiye, 5Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Türkiye
Objectives: To compare the efficacy and safety of platinum-etoposide rechallenge, topotecan and CAV in sensitive relapsed (SR)-SCLC. Methods: It was a retrospective observational study. Patients with SR-SCLC from three oncology centers were included in the study. Clinical outcomes were compared. Results: Of 102 patients, 39.8% (n=41) were treated with topotecan, 43.7% (n=45) with platinum-etoposide, and 16.5% (n=17) with CAV. The mPFS was 2.5 months (95% CI 1.9-3.1) in the topotecan, 5.5 months (95% CI 4.8-6.2) in the platinum-etoposide, and 5.1 months (95% CI 3.1-7.1) in the CAV groups. The difference between the topotecan and platinum-etoposide groups was significant (p < 0.001). The mOS was 3.2 months (95% CI 0.2-6.2) in the topotecan, 11.2 months (95% CI 6.9-15.3) in the platinum-etoposide, and 7.9 months (95% CI 6.3-9.4) in the CAV groups. The difference between topotecan and platinum-etoposide groups was significant (p=0.011). The ORR was 9.8% in the topotecan, 37.8% in the platinum-etoposide, and 41.2% in the CAV groups (p=0.005). Although a trend towards increased toxicity with platinum-etoposide was observed, all three regimens showed similar safety profiles. Conclusion: It was suggested that platinum-etoposide rechallenge improved PFS, OS and ORR with a similar safety profile over topotecan in SR-SCLC. Keywords: Sensitive relapse, SCLC, rechallenge, platinum-etoposide
Cite This Article
Gurler F, Gulesen A, Taban H, Yilmaz F, Seyran E, Dursun E, Eraslan E, Arik Z, Oksuzoglu B, Yazici O, Ozdemir N, Uner A, Gunel N, Ozet A. Real-World Outcomes of Second-Line Treatment in Sensitive Relapsed Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study. EJMI. 2023; 7(3): 321-328
Corresponding Author: Fatih Gurler